...
首页> 外文期刊>Journal of the American College of Cardiology >Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials. A science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation.
【24h】

Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials. A science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation.

机译:卵圆孔未闭的经皮器械闭合术可预防继发性卒中:呼吁完成随机临床试验。美国心脏协会/美国中风协会和美国心脏病学会基金会的科学顾问。

获取原文
获取原文并翻译 | 示例
           

摘要

The optimal therapy for prevention of recurrent stroke or transient ischemic attack in patients with cryptogenic stroke and patent foramen ovale has not been defined. Although numerous observational studies have suggested a strong association between patent foramen ovale and cryptogenic stroke, a causal relationship has not been convincingly established for the majority of affected patients. Treatment choices include medical therapy with antiplatelet agents or vitamin K antagonists, percutaneous device closure, or open surgical repair. Whereas suture closure of an incidental patent foramen ovale is performed routinely during the course of an operation undertaken for another indication, primary surgical repair is rarely advocated in the current era. The choice between medical therapy and percutaneous device closure has been the subject of intense debate over the past several years, albeit one that has not been adequately informed by randomized, prospective clinical trial data to permit an objective comparison of the relative safety and efficacy of these respective approaches. Enrollment in clinical trials has lagged considerably despite frequent calls for participation from the US Food and Drug Administration and major professional societies. Completion and peer review of ongoing trials are critical steps to establish an evidence base from which clinicians can make informed decisions regarding the best therapy for individual patients. The present advisory strongly encourages all clinicians involved in the care of appropriate patients with cryptogenic stroke and patent foramen ovale--cardiologists, neurologists, internists, radiologists, and surgeons--to consider referral for enrollment in these landmark trials to expedite their completion and help resolve the uncertainty regarding optimal care for this condition.
机译:尚未确定预防隐源性中风和卵圆孔未闭的患者复发性中风或短暂性脑缺血发作的最佳疗法。尽管大量的观察性研究表明卵圆孔未闭与隐源性中风之间有很强的联系,但对于大多数受影响的患者,尚无令人信服的因果关系。治疗选择包括抗血小板药物或维生素K拮抗剂的药物治疗,经皮器械闭合或开放式外科手术修复。尽管在为其他适应症而进行的手术过程中,通常会关闭卵圆形的未闭孔的缝合线,但在当前时代很少提倡进行初次手术修复。在过去几年中,药物治疗和经皮器械闭合之间的选择一直是激烈的辩论主题,尽管尚未获得足够的随机,前瞻性临床试验数据来客观比较这些药物的相对安全性和有效性。各自的方法。尽管美国食品药品监督管理局和主要专业协会经常呼吁参加临床试验,但临床试验的入学率却大大下降。完成和正在进行的临床试验的同行评审是建立证据基础的关键步骤,临床医生可以据此做出明智的决定,以针对个别患者进行最佳治疗。本建议强烈鼓励所有参与治疗隐源性中风和卵圆孔未闭的患者的临床医生-心脏病专家,神经科医生,内科医生,放射科医生和外科医生-考虑转诊参加这些具有里程碑意义的试验以加快其完成和提供帮助解决针对这种情况的最佳护理的不确定性。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号